Alembic Limited

ALEMBICLTD.BO·BSE·Real Estate
Compare
92.00−3.15 (−3.31%)today
At close: Oct 21, 3:24 PM IST · May be delayed up to 15 min · INR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close95.15
Open96.05
Day range91.4596.30
52-week range85.55125.70
Off day high−4.47%
Off 52-week high−26.81%
Volume37.90K
Avg. volume (3M)16.01K
Market cap23.62B
EPS (TTM)12.61
Forward P/E—
P/E ratio (TTM)7.30
Dividend yield2.49% (2.40)
Beta (5Y)0.37
Shares outstanding256.78M
Short interest—
Earnings dateAug 11, 2025 (est.)
Analyst target—
Profit margin144.76%

Against its peers

Compare in full ›
ALEMBICLTD.BO APLLTD.BO IOLCP.NS INDOCO.NS AARTIDRUGS.BO IAM
Market cap 23.62B 154.92B 51.14B 21.34B 35.59B 748.93M
P/E (TTM) 7.3 22.3 30.5 723.4 18.6 —
Forward P/E — 16.1 16.8 19.1 14.0 —
Price/book 0.9 2.7 2.8 2.1 2.3 -1.6
Dividend yield 2.49% 1.52% 0.55% 0.08% 0.50% —
1-year change −17.33% −15.06% +92.46% −16.19% −21.36% −15.34%
Today −3.31% −0.26% −4.85% −2.11% −2.29% −1.31%

The closest companies by business and industry (Real Estate - Development). Prices may be delayed up to 15 min.

News18·Positive

Alembic Pharma gets USFDA nod for generic ear infection drug

New Delhi, Oct 19 (PTI) Alembic Pharmaceuticals Ltd on Monday said it has received the final approval from the US Food and Drug Administration (USFDA) for its generic Ciprofloxacin and Dexamethasone Otic Suspension USP. The product is…

InvestyWise·Positive

Alembic Pharmaceuticals: Gets USFDA Approval for Otic Suspension

InvestyWise delivers real-time Indian stock market news, corporate filings, regulatory disclosures, and financial analysis. Track NSE and BSE-listed companies with AI-powered insights for smarter investment decisions. Alembic…

From articles in the 4Search news index.

In the news

5mentions in 30 days
5with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.